A Double-Blind, Placebo-Controlled, Randomized, Crossover, Multicenter Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Subjects With Type 2 Diabetes Mellitus.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 05 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.